Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-07-12

Clinical Trial Update: Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ISU302 in Type 1 Gaucher disease has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ISU302

Snippet

Sponsor: ISU Abxis Co., Ltd. | Conditions: Gaucher Disease, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2017-07-12